Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

BACKGROUND: The NV1020 oncolytic herpes simplex virus type-1 has shown significant promise for the treatment of many different types of tumors in experimental animal models and human trials. Previously, we described the construction and use of the NV1020-like virus OncSyn to treat human breast tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Israyelyan, Anna, Chouljenko, Vladimir N, Baghian, Abolghasem, David, Andrew T, Kearney, Michael T, Kousoulas, Konstantin G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453120/
https://www.ncbi.nlm.nih.gov/pubmed/18518998
http://dx.doi.org/10.1186/1743-422X-5-68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453120/
https://www.ncbi.nlm.nih.gov/pubmed/18518998
http://dx.doi.org/10.1186/1743-422X-5-68

Ejemplares similares